VTCN1 and breast cancer: Of note, because B7-H4 is highly expressed independently of HER2 or PD-L1 expression in breast cancers, they propose the use of this therapeutic agent for PD-L1−B7-H4-expressing tumors or anti-HER2 antibody nonresponsive breast tumors (124).